Highest-materiality recent filing
Elected Parag Mallick and Farzad Nazem as Class II directors with ~97% of votes cast (excluding broker non-votes).
Nautilus Biotechnology Q1 loss narrows to $14.7M; cash $143.4M
Net loss of $14.7M vs $16.6M in Q1 2025; operating expenses down 14% YoY to $16.1M.
Nautilus Biotechnology FY2025 net loss narrows to $59M; cash $156M; guidance for higher 2026 spend
Q4 net loss of $13.8M vs $17.6M YoY; operating expenses down 23% to $15.4M.
Nautilus regains Nasdaq minimum bid price compliance; deficiency closed
Received notice on Nov 3, 2025 that closing bid price met $1 for 10 consecutive days.
Nautilus Biotechnology Q3 2025 net loss $13.6M; operating expenses down 19% to $15.5M
Net loss of $13.6M for Q3 2025, improved from $16.4M loss in Q3 2024.
Nautilus Q2 net loss narrows to $15.0M; cash $179.5M; platform milestone
Operating expenses $17.1M, down 18% YoY from $20.8M.
Nautilus Biotechnology elects Class I directors, ratifies PwC, reduces board size to 7
Sujal Patel re-elected with 84.3M votes for; Matthew McIlwain elected with 82.2M votes for.
Received notice on May 1, 2025 for failing to maintain $1.00 minimum bid price for 30 consecutive business days through April 30, 2025.
Nautilus Q1 net loss $16.6M, operating expenses down 13% YoY
Net loss $16.6M, improved from $18.7M in Q1 2024.
Q4 2024 operating expenses flat at $20.0M; FY2024 op. expenses $81.5M (+7% YoY).
Two Nautilus Biotechnology directors not standing for re-election at 2025 annual meeting
Vijay Pande informed company on Jan 27, 2025, that he will not stand for re-election.
Nautilus Q3 net loss $16.4M, cash $221.2M; OpEx flat YoY at $19.1M
Net loss of $16.4M for Q3 2024, compared to $15.9M loss in Q3 2023.
Nautilus Biotechnology reports Q2 2024 net loss of $18M, operating expenses up 9% YoY
Net loss of $18.0M in Q2 2024 vs $15.8M in Q2 2023.
Nautilus Biotechnology announces 2024 annual meeting voting results
Elected Melissa Epperly (92.1M for, 674K withheld), Matthew L. Posard (90.6M for, 2.1M withheld), Karen Akinsanya (89.9M for, 2.8M withheld) as Class III directors.
Nautilus Q1 net loss $18.7M vs $15.0M YoY; cash $247.7M
Net loss of $18.7M widened from $15.0M in Q1 2023; no revenue reported.
Nautilus Biotechnology enters $125M at-the-market equity offering with TD Cowen
Sales agreement with TD Cowen to sell up to $125M of common stock via ATM program.
Nautilus Biotechnology reports FY2023 net loss $63.7M; cash runway into H2 2026
Net loss $63.7M for FY2023, compared to $57.9M in FY2022; operating expenses $76.2M, up 20% YoY.
Filed suit on Dec 14, 2023 in Northern District of California against Somalogic and Caltech.
Nautilus Biotechnology Q3 net loss $15.9M, op ex up 21% YoY to $19.1M
Net loss of $15.9M for Q3 2023 vs. $14.1M in Q3 2022.
Nautilus Q2 net loss $15.8M; cash runway extended through 2025-2026
Operating expenses $19.0M, up 23% YoY from $15.5M driven by product development headcount.
Nautilus Biotechnology holds 2023 annual meeting; reelects three Class II directors
Stockholders elected Parag Mallick, Matthew McIlwain, and Farzad Nazem as Class II directors with >92M votes for each.
Nautilus Biotech Q1 net loss $15M, cash $302M; platform launch mid-2024
Net loss $15.0M vs $15.8M year ago; operating expenses $18.1M, up 13% YoY on higher headcount.
Nautilus Biotechnology reports FY2022 net loss of $57.9M; cash runway into 2025
Net loss $57.9M for FY2022 vs $50.3M in FY2021; operating expenses $63.6M, up 26%.
Nautilus appoints Karen Akinsanya to Nominating and Governance Committee
Appointment effective October 27, 2022; committee now includes McIlwain (Chair), Pande, and Akinsanya.
Nautilus Biotechnology Q3 2022 net loss $14.1M, cash $323.6M; bylaws amended
Operating expenses $15.8M for Q3 2022, up 9% YoY from $14.6M.
Nautilus Q2 net loss $14.7M; cash $334.9M; platform launch on track for mid-2024
Operating expenses of $15.5M in Q2 2022, down from $16.0M in Q1 2022.
Nautilus Biotechnology stockholders elect three Class I directors and ratify PwC as auditor
Sujal Patel, Vijay Pande, and Michael Altman elected as Class I directors with ~68.5M votes each.
Nautilus Biotechnology Q1 net loss widens to $15.8M on higher R&D and G&A costs
Operating expenses $16.0M, up 90% YoY from $8.4M, driven by headcount and public company costs.
Nautilus Biotechnology appoints Karen Akinsanya, Schrödinger President, to Board
Appointment effective March 30, 2022; Akinsanya will serve as Class III director through 2024.
Nautilus Biotechnology reports FY2021 net loss of $50.3M; operating expenses up 221% to $50.5M
FY2021 net loss $50.3M, compared to $15.6M in 2020; operating expenses $50.5M, up 221%.
Nautilus Q3 net loss widens to $14.5M; OpEx up 262%; cash at $374M
Net loss of $14.5M for Q3 2021 vs. $4.0M loss in Q3 2020.
Nautilus Biotechnology Q2 2021 net loss of $10.7M; raised $345.5M in business combination
Completed business combination with ARYA Sciences, receiving gross proceeds of $345.5M.
each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors
Matthew McIlwain agreed to resign as a Class II director, effective as of the opening of the polls for the election of Class I directors at the Annual Meeting, and to stand for election to the Board as a Class I director at the Annual Meeting
each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors
On January 27 and 28, 2025, each of Vijay Pande and Michael Altman, respectively, informed Nautilus Biotechnology, Inc. (the “Company”) that they will not stand for re-election to the Company’s board of directors at the Company’s 2025 annual meeting of stockholders.
On January 27 and 28, 2025, each of Vijay Pande and Michael Altman, respectively, informed Nautilus Biotechnology, Inc. (the “Company”) that they will not stand for re-election to the Company’s board of directors at the Company’s 2025 annual meeting of stockholders.
On March 30, 2022 , the board of directors (the “Board”) of Nautilus Biotechnology, Inc. (the “Company”), upon recommendation of the Nominating and Governance Committee of the Board, appointed Karen Akinsanya to the Board, effective immediately.
Max materiality 0.75 · Median 0.50 · Most common event earnings